Special Issue "Targeting of Tumor Dormancy Pathway"

A special issue of Onco (ISSN 2673-7523).

Deadline for manuscript submissions: 31 December 2023 | Viewed by 180

Special Issue Editors

Laboratory of Histology-Embryology, Faculty of Medicine, National & Kapodistrian University of Athens, 75 Mikras Asias Street, Goudi, 11527 Athens, Greece
Interests: DNA polymorphisms; RNA; miRNAs; carcinogenesis; bioinformatics; DNA damage; cell cycle; cancer

Special Issue Information

Dear Colleagues,

Dormant tumor cells, also known as minimal residual disease, represent a population of cancer cells that have entered a state of growth arrest, typically after primary tumor removal or during periods of remission. This dormant state allows them to evade conventional cancer therapies, such as chemotherapy or radiation, which primarily target actively dividing cells. It is generally thought that dormant tumor cells have the potential to reactivate and give rise to metastatic tumors years or even decades after initial treatment. However, from another perspective, keeping tumor cells silent for decades can be regarded as tantamount to cure. From both perspectives, it is important to understand the mechanisms underlying dormancy. Keeping tumor cells dormant for indefinite periods of time could form a new strategy of cancer treatment. This Special Issue will highlight the current state of the knowledge in tumor dormancy, targeting of tumor dormancy pathways, and future prospects for exploiting tumor dormancy for cancer therapies.

Dr. Athanassios Kotsinas
Dr. Constantin N. Baxevanis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • dormant tumor cells
  • conventional cancer therapies
  • cancer therapies
  • chemotherapy
  • radiation
  • tumor dormancy
  • targeting of tumor dormancy pathways

Published Papers

This special issue is now open for submission.
Back to TopTop